Collaborative Arrangements and Licensing Agreements - AstraZeneca (Details) $ in Thousands	2 Months Ended		3 Months Ended	12 Months Ended
	Feb. 26, 2026	Feb. 25, 2026	Dec. 31, 2025 USD ($)	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2021 USD ($) Component PerformanceObligation	Dec. 31, 2015 USD ($)	Jul. 31, 2015 USD ($) PerformanceObligation
WAINUA [Member]
Collaborative Arrangements and Licensing Agreements [Abstract]
Maximum amount of payments receivable over term of collaboration			$ 3,600,000	$ 3,600,000
Upfront payment received							$ 200,000
Maximum amount of development milestone payments over term of collaboration			485,000	485,000
Maximum amount of sales milestone payments over term of collaboration			2,900,000	$ 2,900,000
Number of material components (in Component) | Component							4
Number of separate performance obligations (in PerformanceObligation) | PerformanceObligation							1
Transaction price							$ 200,000
Revenue						$ 20,000
Percentage of costs associated with ongoing global Phase 3 development program paid by AstraZeneca				55.00%
WAINUA [Member] | U.S [Member] | Plan [Member]
Collaborative Arrangements and Licensing Agreements [Abstract]
Percentage of costs associated with ongoing global Phase 3 development program paid by AstraZeneca	75.00%	75.00%
WAINUA [Member] | Rest of the World [Member] | Plan [Member]
Collaborative Arrangements and Licensing Agreements [Abstract]
Percentage of costs associated with ongoing global Phase 3 development program paid by AstraZeneca	87.50%	87.50%
WAINUA [Member] | Maximum [Member]
Collaborative Arrangements and Licensing Agreements [Abstract]
Royalty percentage received on sales of medicine in U.S.				20.00%
Next payment to be achieved			200,000	$ 200,000
WAINUA [Member] | Minimum [Member]
Collaborative Arrangements and Licensing Agreements [Abstract]
Cumulative payments received			575,000	575,000
Next payment to be achieved			115,000	115,000
WAINUA [Member] | ATTRv-PN [Member]
Collaborative Arrangements and Licensing Agreements [Abstract]
Revenue					$ 30,000
Cardiovascular, Renal and Metabolic Diseases [Member]
Collaborative Arrangements and Licensing Agreements [Abstract]
Maximum amount of payments receivable over term of collaboration			3,400,000	3,400,000
Upfront payment received								$ 65,000
Maximum amount of development milestone payments over term of collaboration			444,000	444,000
Maximum amount of sales milestone payments over term of collaboration			2,100,000	2,100,000
Next payment to be achieved			15,000	15,000
Number of separate performance obligations (in PerformanceObligation) | PerformanceObligation									1
Transaction price									$ 65,000
Revenue			20,000
Maximum amount of license fees over term of collaboration			175,000	175,000
Maximum amount of regulatory milestone payments over term of collaboration			593,000	593,000
Cumulative payments included in transaction price for performance obligation			90,000	$ 90,000
Cardiovascular, Renal and Metabolic Diseases [Member] | Maximum [Member]
Collaborative Arrangements and Licensing Agreements [Abstract]
Royalty percentage received on net sales of medicine				10.00%
Cardiovascular, Renal and Metabolic Diseases [Member] | Minimum [Member]
Collaborative Arrangements and Licensing Agreements [Abstract]
Cumulative payments received			400,000	$ 400,000
AstraZeneca [Member]
Collaborative Arrangements and Licensing Agreements [Abstract]
Revenue				147,295	129,759	$ 202,236
Deferred contract revenue			$ 0	$ 0	$ 0